Watch CURX. Know when insiders buy.
One email the day a filing lands. Free.
CURX
Curanex Pharmaceuticals Inc
5.01
+0.25 +5.14%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $157.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$10.5MNET CASH —52W 3.66 – 16.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.3M | −$3.3M | — | -0.12 | −$1.1M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$3.2M | −$3.2M | — | -0.11 | −$955K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$3.1M | −$3.1M | — | -0.12 | −$857K | — | — | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$951K | −$954K | — | -0.04 | −$9.2M | — | — | Nov 17 |
| Q2 2025 · Jun 30 | — | — | — | −$58K | −$60K | — | 0.00 | −$290K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$137K | −$138K | — | -0.01 | −$150K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$147K | −$146K | — | 0.02 | −$95K | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$93K | −$91K | — | -0.04 | −$130K | — | — | Nov 17 |
| Q2 2024 · Jun 30 | — | — | — | −$44K | −$44K | — | -0.02 | — | — | — | Nov 17 |
| Q1 2024 · Mar 31 | — | — | — | — | −$80K | — | — | — | — | — | Nov 17 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$4.2M | −$4.2M | — | -0.17 | −$10.5M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$365K | −$362K | — | -0.03 | −$556K | — | — | — | — |
Every number comes from Curanex Pharmaceuticals Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.